APT(SH:688617) Sou Hu Cai Jing·2025-08-22 16:47Core Viewpoint - Huatai Medical's stock price has experienced a decline, while the company shows strong revenue and profit growth in its latest financial report, indicating potential investment opportunities in the medical device sector [1][2]. Group 1: Company Overview - Huatai Medical focuses on the research, production, and sales of cardiac electrophysiology and interventional medical devices [1]. - The company's main products include coronary access products for PCI procedures and electrophysiology products such as three-dimensional cardiac electrophysiology mapping systems [1]. - The business layout emphasizes a complete range of coronary access and cardiac electrophysiology medical devices, with peripheral vascular and non-vascular interventional medical devices as key development areas [1]. Group 2: Financial Performance - In the first half of 2025, Huatai Medical achieved operating revenue of 1.21 billion yuan, a year-on-year increase of 21.3% [1]. - The net profit attributable to shareholders reached 425 million yuan, reflecting a year-on-year growth of 24.11% [1]. - The company reported overseas business revenue of 143 million yuan, which represents a year-on-year increase of 34.56% [1]. Group 3: Investment Activities - Huatai Medical plans to jointly invest 15 million yuan with related parties in Shanghai Liliang Medical Technology Co., Ltd. [1]. - The founder, Cheng Zhenghui, intends to reduce his holdings by no more than 2.82 million shares, accounting for 2% of the total share capital [1]. Group 4: Market Activity - On August 22, 2025, Huatai Medical's stock price was 280.59 yuan, down 1.20% from the previous trading day, with a trading volume of 44,978 hands and a transaction amount of 1.27 billion yuan [1]. - The net inflow of main funds into Huatai Medical was 40.11 million yuan, representing 0.1% of the circulating market value [2].